ADiTx Inc. recently participated in Wall Street Reporters' Next Super Stock live stream, where the company's management discussed their strategic initiatives and future prospects. Aditxt is currently valued at a $5 million market cap, and according to Jack Marks, presents a significant upside potential with multiple catalysts in place for growth. The company is targeting major market opportunities in oncology, autoimmunity, and women's health. The management emphasized the importance of executing key projects like Pearsanta commercialization, Adimune human trials, and the acquisition of Evofem to transition Aditxt from a speculative entity to a tangible success by 2026. Unfortunately, the URL for the full speech/interview was not provided in the document.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。